결핵연구원

Collaborating Institutions

Established in 1992, BIONEER is the first genetic-based 'bioventure' company focusing on disease prevention, diagnosis, treatment, and enhancing competitiveness in biotechnology R&D globally.
The Korean Institute of Tuberculosis is developing a system for the detection and diagnosis of non-tuberculous mycobacteria in collaboration with Bionia.

Optipharm engages in businesses such as animal disease diagnosis, animal pharmaceuticals, bacteriophage, Medipig, xenotransplantation, and VLP vaccines. Leveraging its accumulated technological expertise in the animal sector, Optipharm is expanding its scope into the human sector.
The Korean Institute of Tuberculosis is conducting a research project on bacteriophage therapy in collaboration with OptiPharm

BodytechMed was established as an antibody development and manufacturing company. Recognizing the future potential of the diagnostic market in the early 2000s, it became the first in the industry to transition its business direction to the diagnostic device sector. Over the past 20 years, it has grown into a leading company in on-site immune diagnostics
BodytechMed, the Korean Institute of Tuberculosis, and Asan Medical Center are conducting joint research aimed at developing a field test method capable of simultaneous diagnosis of latent and active tuberculosis

LigaChem Biosciences Bio is a research-driven pharmaceutical company focusing on global new drug R&D based on medicinal chemistry.
The Korean Institute of Tuberculosis is conducting an evaluation of the antimicrobial activity against MABC based on semi-quantitative changes in sputum culture results following adjunctive administration of LCB01-0371 in patients with refractory MABC, as part of the central laboratory for the Delafloxacin clinical trial study involving 20 patients.